On November 23, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the following virtual investor conferences in December (Press release, CRISPR Therapeutics, NOV 23, 2021, View Source [SID1234595964]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th Annual Evercore ISI HealthCONx Conference
Date: Wednesday, December 1, 2021
Time: 12:35 p.m. ET

Piper Sandler 33rd Annual Healthcare Conference
Date: Thursday, December 2, 2021
Time: 1:00 p.m. ET

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.

On November 23, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of its Interim Report for the period January – September 2021 (Press release, Allarity Therapeutics, NOV 23, 2021, View Source [SID1234595982]). The report is available as an attached document and on the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve Carchedi, CEO of Allarity Therapeutics, commented on the company’s accomplishments during the period, stating, "It continues to be an exciting time for Allarity and the third quarter of 2021 was no exception. We are now close to a pivotal event in the company’s history: Becoming a US-based company listed on Nasdaq in the US. In parallel to preparing for this pivotal event, we achieved several significant milestones during Q3, including the agreement on irofulven with Lantern Pharma and receiving an acceptance & review notification from the FDA for our pre-market approval (PMA) application for the Dovitinib-DRP companion diagnostic. In line with this progress, in September, we announced our agreement with Lonza Group for the manufacturing of dovitinib. Regarding IXEMPRA and stenoparib, our focus has been on expanding our active clinical trial sites for both programs. Based on this level of overall progress, I remain very optimistic about what Allarity can accomplish once our transformation to becoming a US NASDAQ-listed company is complete."

Summary of the Interim Report for Q3 2021

Consolidated group revenue amounted to 0 MDKK (0 MDKK).
Consolidated group loss before depreciation amounted to -20.3 MDKK (-11.8 MDKK).
Consolidated group loss before net financials amounted to -20.4 MDKK (-12.0 MDKK).
Consolidated net result amounted to -20.6 MDKK (-8.5 MDKK).
Consolidated earnings per share (EPS) amounted to -0.05 DKK (-0.05 DKK).

2020 numbers in brackets.

Highlights during Q3 2021

July

On July 5, Allarity Therapeutics received acceptance & review notification from the U.S. FDA for the Company’s pre-market approval application for the DRP for dovitinib.
On July 7, Allarity Therapeutics issued share units as payment-in-kind for services rendered during the Rights Issue in Q2 2021
On July 25, the company announced that it had entered into an agreement with Lantern Pharma for future clinical development of irofulven.

August

On August 5, the company announced that its oral PARP inhibitor, stenoparib, had demonstrated additional pre-clinical antiviral activity against new variants of Coronavirus.
On August 16, the company published a notice to convene an Extraordinary General Meeting to be held on August 31.
On August 18, the company published an elaboration on the contents of the meeting agenda for the Extraordinary General Meeting announced on August 16.
On August 19, the company announced a new publication date for the publication of the Q2 2021 interim report.
On August 19, the company published the interim report for the period January – June 2021.
On August 23, the company announced that it had filed a Form S-4 Registration Statement with the U.S. Securities & Exchange Commission for Listing of Allarity Therapeutics, Inc. on U.S. Nasdaq.
On August 26, the company announced an extraordinary exercise period for warrants of series ALLR TO 3 set to August 30 – September 13.
On August 31, the company published the minutes of the extraordinary general meeting held announced on August 16.

September

On September 14, the company announced that it had received approximately SEK 16.5 million from subscription to warrants of series ALLR TO 3.
On September 15, the company announced an update to the announcement of the outcome of exercise of the ALLR TO 3 warrants, Allarity had received approximately SEK 23.3 million.
On September 16, the company announced that it would present dovitinib survival data from DRP-screened RCC patients at the ESMO (Free ESMO Whitepaper) 2021 Virtual Congress.
On September 23, the company announced it would collaborate with Lonza Group to Manufacture dovitinib, Allarity’s most advanced clinical therapeutic candidate.
Highlights after the period

November

On November 5, the company announced that the U.S. SEC had issued an order declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement effective.
On November 5, the company published a notice of an extraordinary general meeting to be held on November 22, 2021.
On November 11 the company’s oral PARP inhibitor, stenoparib, had demonstrated pre-clinical antiviral activity against the delta variant of Coronavirus.
On November 22, the Extraordinary General Meeting approved the Reorganization Agreement, initially announced on May 20, 2021.
The report is available on: View Source

On November 23, 2021 ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, reported the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters’ option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock, for additional gross proceeds of $10.5 million for total gross proceeds of $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay (Press release, ViewRay, NOV 23, 2021, View Source [SID1234595999]). All of the shares sold in the offering were sold by ViewRay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.

Piper Sandler and Stifel acted as the joint book-running managers for the offering. Guggenheim Securities also acted as a book-running manager for the offering. B. Riley Securities and BTIG acted as co-managers for the offering.

A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission ("SEC") and automatically became effective upon filing. This offering was made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website located at View Source Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [email protected], or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

On November 23, 2021-Defence Therapeutics Inc., reported the establishment of an agreement with the Lady Davis Institute cell processing center (CPC) to initiate manufacturing of its AccumTM DC cancer vaccine candidate AccuVAC-D001 (Press release, Defence Therapeutics, NOV 23, 2021, View Source [SID1234626240]). This agreement immediately positions Defence’s vaccine to be manufactured with the focus on melanoma and breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The mandate of the Jewish General Hospital CPC located at the Lady Davis Institute is to support early phase clinical trials of cell-based therapies where processing of human cell and tissue is required to treat human catastrophic illnesses such as cancer. The close proximity of this facility to hospital patients further simplifies the logistics of the trial.

The facility comprises of the Clean Room area where cell processing takes place, as well as the Laboratory Annex supporting the Clean Room. The Clean Room is a clinical-grade, high sterility isolation facility certified ISO Class 7. It is operated by highly qualified personnel led by Dr. Nicoletta Eliopoulos, a pioneer in cell therapy with a track record of successful implementation and prosecution of custom autologous cellular pharmaceuticals.

"We are a step closer to initiate our Phase I trial using our proprietary AccumTM DC technology with the establishment of such agreement. These studies will not only establish the "blueprints" of our manufacturing process, but they will implement import quality control steps required by regulatory agencies prior to treating melanoma and breast cancer patients in 2022", says Mr. Plouffe, CEO of Defence Therapeutics.

On November 23, 2021 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that it will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021 (Press release, Myovant Sciences, NOV 23, 2021, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-participate-evercore-isi-4th-annual-healthconx [SID1234595965]). David Marek, Chief Executive Officer of Myovant Sciences, Inc. will participate in a fireside chat at 11:45 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to the Evercore fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.